Farglitazar

Drugbox
IUPAC_name = "N"-("o"-benzoylphenyl)-"O"- [2-(5-methyl- 2-phenyl-4-oxazolyl)ethyl] -L-tyrosine

---

CAS_number = 196808-45-4
CAS_supplemental =
ATC_prefix =
ATC_suffix =
ATC_supplemental =
PubChem = 170364
DrugBank =
chemical_formula =
C=34 | H=30 | N=2 | O=5
molecular_weight = 546.612 g/mol
bioavailability =
protein_bound =
metabolism =
elimination_half-life =
excretion =
pregnancy_AU =
pregnancy_US =
pregnancy_category=
legal_AU =
legal_CA =
legal_UK =
legal_US =
legal_status =
routes_of_administration =

Farglitazar is a is a peroxisome proliferator-activated receptor agonist which is being developed by GlaxoSmithKline for the treatment of hepatic fibrosis. It is currently in phase II clinical trials.